Matthew Galsky, MD | Authors


Phase II Trial Considers the Benefit of Switch Maintenance in Urothelial Cancer

July 24, 2019

Matthew Galsky, MD, discusses how the phase II HCRN GU14-182 study helps to define the role of switch maintenance therapy in patients with urothelial cancer. The study looked at maintenance with pembrolizumab versus placebo following frontline chemotherapy in patients with metastatic urothelial cancer.

The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer

October 11, 2016

Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.